Precision Oncology Analysis & Strategy
The flagship service: a structured review of the clinical, pathological, molecular and evidentiary dimensions of a complex cancer case.
- Complex cases where standard pathways have been exhausted or are contested.
- Rare cancers, cancers of unknown primary, and treatment-resistant disease.
- Cases with extensive molecular data and no clear reading of it.
- Full clinical history and disease trajectory, reconstructed as a single narrative
- Pathology, immunohistochemistry and imaging reports, including internal consistency between them
- Somatic and germline molecular data, with assay design and limits of detection assessed
- Transcriptomic, multi-omic and single-cell data where available
- ctDNA and longitudinal molecular results, including trajectory over time
- Pharmacogenomic considerations relevant to systemic therapy
- Prior therapy, sequence, tolerability and documented response
- Resistance patterns and what the molecular record suggests about them
- The relevant scientific and clinical evidence base, including where it is thin
- The clinical trial landscape, assessed for plausible fit rather than keyword match
- A structured written analysis of the case
- Molecular interpretation with explicit evidence tiers
- A synthesis of the relevant evidence, including where it is thin
- Potentially relevant biomarkers and trial avenues
- A discussion framework for the treating team
- Monitoring considerations where relevant
- Analysis and interpretation are provided to you and, where you wish, directly to your treating team — who continue to prescribe, administer and direct your treatment.
- The work sits alongside your treating oncologist and is designed to strengthen that relationship rather than sit outside it.
- It is built for considered review. Anything acute or time-critical belongs with your treating team or your local emergency service, who can act immediately.
- It sets out what the evidence supports and where it remains uncertain. It does not forecast how a particular cancer will respond.
- The analysis is written to be used by your treating team, and is issued in a form they can act on rather than as a parallel plan.
How a case is worked through
Seven stages, always in this order. Molecular findings read before the clinical context is established tend to be over-weighted, and evidence assessed before the molecular picture settles tends to answer the wrong question.
-
Case intake
The clinical question is defined and the documentary record is assembled. What is missing is identified at this stage rather than discovered later.
-
Data review
Clinical history, pathology, imaging reports and treatment history are read as a single record, and inconsistencies are noted.
-
Molecular interpretation
Somatic and germline findings are interpreted in context, with assay limitations made explicit.
-
Evidence synthesis
The relevant literature, biomarker evidence and trial landscape are assembled, including an honest account of where the evidence is thin.
-
Clinical strategy discussion
The analysis is discussed — with the patient, the referring clinician, or both — as a set of questions and options rather than a single instruction.
-
Report
A structured written analysis is issued, recording both the conclusions and the uncertainties behind them.
-
Follow-up and coordination
Where appropriate, follow-up supports the treating team as the case develops or as new results arrive.
Getting started
Nothing is charged for an enquiry, and scope is agreed in writing before any work starts.
Enquiries begin with a short message describing the situation and the question. From there, the documentation needed is agreed, and a scope and timeline are confirmed before any work starts.
The document checklist sets out what is typically needed. Missing items are worth identifying at the outset rather than mid-review.